– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company…
Toronto, Ontario--(Newsfile Corp. - August 16, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a…
Brown brings years of industry expertise to oversee and maximize 4G Clinical's operational efficiency and excellence. WELLESLEY, Mass., Aug. 15,…
Potentially pivotal GBM study evaluating lead program, Berubicin, enrollment completed; Topline data expected in the first half of 2025Recent strategic…
Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's…
First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBMPart B expected…
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…
VANCOUVER, BC / ACCESSWIRE / August 15, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to…
Marlborough, Massachusetts--(Newsfile Corp. - August 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary…
Prepares for September 17, 2024, Evie Ring back in stock dateAnnounces brand partnership with digital creator Heidi D'AmelioFocuses on launch…